AdvanCell

Recent Finacing

Grant

Recent Raise

$18M

AdvanCell develops Pb-212-based targeted alpha therapies and operates an on‑demand alpha isotope generator with in‑house radiopharmaceutical manufacturing to support clinical trials and partner supply.

Founded 2019

New South Wales, Australia

11-50

Private

advancell.com.au

Highlights

Focus Areas

Biotechnology

Clinical Trials

Oncology

Pharmaceutical

Recent Investors

M

Financials

$142.4M

Total Raised

3

Funding rounds

8

Investors

Team

Upgrade to view the team

See the team members at AdvanCell.